Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Nortriptyline Action Pathway
Homo sapiens
Drug Action Pathway
Nortriptyline is a tricyclic antidepressant used to treat major depression. Nortriptyline hydrochloride, the active metabolite of amitriptyline, is a tricyclic antidepressant (TCA). This drug is also used off-label and it includes the treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome. Nortriptyline exerts antidepressant functions by inhibiting the reuptake of serotonin and norepinephrine in the neurons. It is possible by its binding to the sodium-dependent noradrenaline transporter and to the sodium-dependent serotonin transporter. This drug displays a more selective reuptake inhibition for noradrenaline, which may explain increased symptom improvement after nortriptyline therapy. As with other tricyclics, nortriptyline displays an affinity for other receptors including mACh receptors, histamine receptors, and 5-HT receptors, in addition to other receptors. This drug is administered as a tablet or as an oral solution.
References
Nortriptyline Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Nelson JC, Kennedy JS, Pollock BG, Laghrissi-Thode F, Narayan M, Nobler MS, Robin DW, Gergel I, McCafferty J, Roose S: Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999 Jul;156(7):1024-8. doi: 10.1176/ajp.156.7.1024.
Pubmed: 10401446
Fabre LF, Scharf MB, Itil TM: Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry. 1991 Jun;52 Suppl:62-7.
Pubmed: 2050651
Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48. doi: 10.1038/sj.bjp.0707253. Epub 2007 Apr 30.
Pubmed: 17471183
Overo KF: Pharmacokinetic aspects on once-daily nortriptyline administration. Neuropsychobiology. 1980;6(1):34-41. doi: 10.1159/000117730.
Pubmed: 7366812
Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. doi: 10.1007/BF02244985.
Pubmed: 7855217
Barker EL, Blakely RD: Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996 Oct;50(4):957-65.
Pubmed: 8863842
Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. doi: 10.1016/s0014-2999(97)01393-9.
Pubmed: 9537821
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings